Genome Canada plans to establish a series of patent offices to accelerate and add value to intellectual property (IP) being generated by its five affiliated regional genome centres. The offices — contingent upon new funding — are modelled on the patent operations of large pharmaceutical companies and would also bundle technologies to make them more attractive to private sector investors.